Does inflammatory breast cancer affect both breasts at the same time?
Answers from top 12 papers
More filters
| Papers (12) | Insight |
|---|---|
| Higher tissue levels of inflammatory markers, mainly the pro-inflammatory ones, are associated with less involuted breasts and may consequently be associated with an increased risk of developing breast cancer. | |
| Inflammatory breast cancer appears to alter the prognosis in association with the receptor status and molecular subtypes. | |
26 Citations | Breast cancer affects both the patient and her loved ones. |
| Our multiple-case inflammatory and non-inflammatory breast cancer families may reflect aggregation of common genetic and/or environmental factors predisposing to both types of breast cancer. | |
90 Citations | These results support previous speculations that male breast cancer is influenced not only by tissue at risk, but also by hormonal and inflammatory factors. |
| These results suggest that the interaction between inflammation and CSCs may affect the tumorigenesis and progression of breast cancer. | |
316 Citations | Induction combination chemotherapy administered with radiation therapy, mastectomy, both, or with additional chemotherapy favorably alters the natural history of inflammatory breast cancer. |
Open access•Journal Article | The risk associated with these histological factors appears to be equal in both breasts, suggesting that these factors are best considered markers of generalized increased breast cancer risk rather than direct precursor lesions. |
09 Jan 2014 | Qualitatively, there seems to be a greater difference in genetic profile in tumors appearing simultaneously on different breasts when compared to multiple tumors on the same breast. |
56 Citations | Here they report that inflammatory breast cancer from American women shows a higher incidence of viral sequences (71%) than sporadic breast cancers. |
| I propose that the unique presentation of inflammatory breast cancer might require specific, identifiable changes in the breast parenchyma that occur before the tumour-initiating event. | |
Open access•Journal Article | These data suggest that there is an increased MVD in breast cancer with the inflammatory phenotype as compared with breast cancer without the inflammatory phenotype. |
Related Questions
How does systemic inflammation contribute to the development and progression of cancer?5 answersSystemic inflammation plays a crucial role in the development and progression of cancer by influencing key elements of carcinogenic mechanisms. Chronic inflammation, whether preexisting or tumor-elicited, can promote tumor initiation, progression, and metastasis by perturbing the tumor microenvironment. Inflammatory mediators and immune cells within the tumor microenvironment can alter cancer-related genes, posttranslational modifications of cellular proteins, and influence processes like cell cycle regulation, DNA repair, and apoptosis. At a systemic level, chronic inflammation is characterized by elevated levels of inflammatory mediators, acute phase proteins, changes in leukocyte populations, and disturbances in the hemostasis system, all of which contribute to the risk of developing malignancies and impacting tumor progression. Targeting inflammation through immunomodulatory strategies or nanomedicine-based drug delivery approaches presents promising avenues for cancer prevention and therapy.
What is the incidence of inflammatory breast cancer in women?5 answersThe incidence of inflammatory breast cancer (IBC) in women ranges from 1% to 5% of all breast cancer cases in the United States. IBC is a rare subtype of locally advanced breast cancer, accounting for about 2% to 4% of breast cancer cases in the US. It is characterized by diffuse induration of the skin with an erysipeloid appearance and rapid onset of symptoms within 3 months. IBC presents with signs such as erythema, edema, nipple inversion, and warmth of the affected breast. The overall incidence rate of IBC is 2.76 cases per 100,000 people, with higher rates observed in black patients (4.52 cases per 100,000) compared to white patients (2.63 cases per 100,000). Inflammatory breast cancer accounts for 8% to 10% of all breast cancer-related deaths.
Does exercise affect proinflammatory cytokine production in breast cancer patients?4 answersExercise has been shown to have an impact on proinflammatory cytokine production in breast cancer patients. Multiple studies have demonstrated that exercise training can lead to a reduction in the levels of proinflammatory cytokines such as IL-6, TNF-α, and IL-8. Specifically, exercise has been found to significantly improve the serum concentrations of IL-6, TNFα, and IL-8. However, the effects of exercise on other proinflammatory cytokines such as IL-10, IL-1β, and INF-ɣ are less clear, with some studies showing no significant changes in their levels following exercise training. Overall, exercise training has been found to positively modulate chronic low-grade inflammation in breast cancer survivors, which may have implications for inhibiting breast cancer recurrence and improving prognosis.
What is Inflammatory breast cancer?4 answersInflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer characterized by diffuse induration of the skin with an erysipeloid appearance. It is clinically defined as erythema and edema occupying at least one-third of the breast, with or without an underlying palpable mass. Diagnostic criteria for IBC include rapid onset of breast erythema, edema, and/or peau d’orange, duration of history no more than six months, erythema occupying at least one-third of the breast, and pathologic confirmation of invasive carcinoma. IBC is generally included in the "chest wall disease" spectrum of breast tumors due to its radical involvement of the skin. The management of IBC is multidisciplinary, with personalized radiation therapy and chemotherapy based on clinical response and clinicopathological features. Systemic staging is recommended to rule out distant metastases. Research is ongoing to improve treatment strategies and increase rates of curable resections, including immunotherapy and targeted and biologic agents.
Is there a correlation between acute inflammation to tumors and the efficacy of cancer immunotherapy?4 answersChronic inflammation is known to play a pivotal role in cancer development by creating an inflammatory tumor microenvironment (TME). This TME consists of pro-inflammatory cells, immune cells, stromal cells, and other components that promote cancer development by stimulating oncogenic signaling pathways and immune escape. Inflammation within the tumor environment is correlated with disease progression and prognosis in many cancers. Cancer cells have also found ways to evade the immune response, leading to immunosuppression. The clinical application of immune checkpoint therapy (ICT) has shown promise in cancer treatment, but its efficacy is limited by the immunosuppressive microenvironment. In a murine model of lung cancer, chronic inflammation induced T-cell exhaustion and an immunosuppressive microenvironment, which affected the efficacy of anti-PD-1 treatment. These findings suggest a correlation between acute inflammation, tumor progression, and the efficacy of cancer immunotherapy.
Is inflammatory breast cancer contagious?10 answers